51075-28-6

Upstream product

• 104-53-0 3-phenyl-propionaldehyde 
• 84782-53-6 3-phenyl-2-(phenylseleno)propionaldehyde 
• 75-15-0 carbon disulfide 
• 7726-95-6 bromine 
• 122-97-4 3-Phenyl-1-propanol 
• 97294-89-8 2-bromo-3-phenylpropanal dimethylacetal 
• 104-54-1 3-Phenylpropenol 
• 107-02-8 acrolein 

Downstream Products

• 50353-41-8 2-Hydroxy-3-phenylpropanal 
• 38559-23-8 1-oxo-3-phenylpropan-2-yl acetate 
• 104-53-0 3-phenyl-propionaldehyde 
• 501-52-0 3-Phenylpropionic acid 
• 828-01-3 phenyllactic acid 
• 103-25-3 3-phenylpropanoic acid methyl ester 
• 2021-28-5 ethyl dihydrocinnamate 
• 22847-18-3 cyclohexyl 3-phenylpropionate 
• 726-26-1 phenyl 3-phenylpropanoate 
• 33124-08-2 5-benzyl-oxazol-2-ylamine 
• 121952-97-4 5-(phenylmethyl)-1,3-thiazol-2-amine 

Relevant academic research and scientific papers

Copper-Mediated Dichotomic Borylation of Alkyne Carbonates: Stereoselective Access to (E)-1,2-Diborylated 1,3-Dienes versus Traceless Monoborylation Affording α-Hydroxyallenes

A mild copper-mediated protocol has been developed for borylation of alkynyl cyclic carbonates. Depending on the nature of the borylating reaction partner, either stereoselective diborylation of the propargylic surrogate takes place, providing convenient access to (E)-1,2-borylated 1,3-dienes, or traceless monoborylation occurs, which leads to α-hydroxyallenes as the principal product. The dichotomy in this borylation protocol has been scrutinized by several control experiments, illustrating that a relatively small change in the diboron(4) reagent allows for competitive alcohol-assisted protodemetalation to forge an α-hydroxyallene product under ambient conditions.

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

Non-imidazole histamine H3 ligands. Part VI. Synthesis and preliminary pharmacological investigation of thiazole-type histamine H3-receptor antagonists with lacking a nitrogen nucleus in the side chain

Background: Antagonists to the H3 receptor are considered to be potential drugs for the treatment of Alzheimer's disease, attention deficit-hyperactive disorder, memory and learning deficits, and epilepsy. The initial development of potent H3 receptor antagonists focused on extensive modification of the natural ligand histamine. However, it has appeared that imidazole-containing ligands are associated with inhibition of cytochrome P450 enzymes, caused by imidazole nitrogen complexation to heme iron in the active site of the enzyme. For these reasons, the development of potent non-imidazole H3 receptor antagonists was eagerly awaited. Objective: Previously, we reported the synthesis and pharmacological in vitro characterization of series of potent histamine H3-receptor non-imidazole antagonists belonging to the class of substituted 2-thiazol-4-n-propylpiperazines. A lead compound 1 of this family was a derivative carrying the ethylaminomethylpropyl chain. Methods: With the aim of increasing lipophilicity, that will help the ligands to cross the blood-brain barrier, we synthesized a series of new 2-thiazol-4-n-propylpiperazines where the ethylaminomethylpropyl moiety was replaced by a p-substituted-, an unsubstituted benzene ring, and ω-phenylalkyl substituent at positions 4 and 5 of thiazole ring, respectively. All compounds were tested for H3 antagonistic effects in vitro using the electrically contracting guinea pig jejunum. Results: The most active compounds of presented series 3d, 3e, and 3j showed lower affinity than the lead compound 1 and additionally, derivatives 3d and 3j possessed weak, competitive H1-antagonistic activity. This is in contrast to the lead compound 1 that has no affinity at H1 receptor. Conclusion: We can conclude that a side chain in the 2-thiazol-4-n-propylpiperazine scaffold should contain a basic center and should be present at a favorable position 5 of thiazole ring.

Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors

A novel series of heat shock protein 90 (Hsp90) inhibitors was identified by X-ray crystal analysis of complex structures at solvent-exposed exit pocket C. The 2-amino-pyrrolo[2,3-d]pyrimidine derivatives, 7-deazapurines substituted with a benzyl moiety at C5, showed potent Hsp90 inhibition and broad-spectrum antiproliferative activity against NCI-60 cancer cell lines. The most potent compound, 6a, inhibited Hsp90 with an IC50of 36?nM and showed a submicromolar mean GI50value against NCI-60 cell lines. The interaction of 6a at the ATP-binding pocket of Hsp90 was confirmed by X-ray crystallography and Western blot analysis.

Novel pyrrolo pyrimidine derivatives and composition for preventing or treating cancer comprising the same

The present invention relates to a novel pyrrolo pyrimidine compound represented by chemical formula 1, pharmaceutically acceptable salt or hydrate thereof, a manufacturing method thereof, and a pharmaceutical composition comprising the compound for preventing or treating cancer. In chemical formula 1, R^1, R^2, R^3, R^4, R^5, and X are the same as defined in the specification.COPYRIGHT KIPO 2016

Iridium-catalyzed isomerization/bromination of allylic alcohols: Synthesis of α-bromocarbonyl compounds

α-Brominated ketones and aldehydes, with two adjacent electrophilic carbon atoms, are highly valuable synthetic intermediates in organic synthesis, however, their synthesis from unsymmetrical ketones is very challenging, and current methods suffer from low selectivity. We present a new, reliable, and efficient method for the synthesis of α-bromocarbonyl compounds in excellent yields and with excellent selectivities. Starting from allylic alcohols as the carbonyl precursors, the combination of a 1,3-hydrogen shift catalyzed by iridium(III) with an electrophilic bromination gives α-bromoketones and aldehydes in good to excellent yields. The selectivity of the process is determined by the structure of the starting allylic alcohol; thus, α-bromoketones formally derived from unsymmetrical ketones can be synthesized in a straightforward and selective manner. Synthon shuffle: An efficient and high-yielding synthetic route to prepare α-bromoketones and aldehydes is presented (see scheme, Cp=pentamethylcyclopentadienyl). The method relies on 1,3-hydrogen shift/bromination of allylic alcohols catalyzed by IrIII complexes. The products are obtained in excellent yields and as single constitutional isomers.

A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation

In this work, we report a rational structure-based approach aimed at the discovery of new 2-aminoimidazoles as β-secretase inhibitors. Taking advantage of a microwave-assisted synthetic protocol, a small library of derivatives was obtained and biologicall

HETEROCYCLIC GAMMA SECRETASE MODULATORS

The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise ad

Direct asymmetric bromination of aldehydes catalyzed by a binaphthyl-based secondary amine: Highly enantio- and diastereoselective one-pot synthesis of bromohydrins

One-pot stereoselective synthesis of bromohydrins as a useful chiral building block was achieved by the reaction of Grignard reagents with optically active α-bromoaldehydes, which were in situ generated by direct asymmetric bromination of aldehydes cataly

IMIDAZOPYRIMIDINONES AND USES THEREOF

The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.